NASDAQ , VICL
Vical Inc. researches and develops biopharmaceutical products based on its deoxyribonucleic acid, better known as DNA, delivery technologies. Vical has gained access to enhancing technologies through licensing and collaborative agreements. Vical, together with its licensees and collaborators, is developing a number of DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cancer and cardiovascular diseases. Vical’s independent development focus is on the cancer immunotherapeutics Allovectin-7 and IL-2/EP, as well as a plasmid vaccine for cytomegalovirus. Its areas of research encompass vaccines for use in high-risk populations for infectious disease targets; vaccines for general pediatric or adult populations for infectious disease applications, and cancer vaccines or immunotherapies, which complement its existing programs and core expertise.
Value
Total number of shares outstanding as of Aug. 5 23,500,000
Price of each share of common stock on Aug. 5 $5.31
Aggregate market value as of Aug. 5 $124,785,000
Performance Record
For year ended Dec. 31, in thousands, except per-share data.
2004 2003 2002
Total revenues $14,545 $8,078 $7,007
Net income (loss) ($23,733) ($24,450) ($27,932)
Net income (loss) per share ($1.05) ($1.22) ($1.39)
Total assets $101,226 $110,707 $129,426
Directors
Robert H. Campbell, 67, director since 2003.
R. Gordon Douglas, 70, chairman since 1999.
M. Blake Ingle, 62, director since 1996.
Gary A. Lyons, 53, director since 1997.
Robert C. Merton, 60, director since 2002.
Vijay B. Samant, 52, director since 2000.
Executive Compensation
Officer 2004 Cash Compensation
Vijay B. Samant, chief executive officer and president $580,000
David C. Kaslow, chief scientific officer $375,000
Jill M. Church, vice president, chief financial officer, secretary $92,788
Martha J. Demski, former vice president, CFO, treasurer, secretary $168,357
Alan Dow, former vice president, general counsel $145,026
Significant Stock Ownership
Number of shares Percent
March 1
Merrill Lynch & Co., Inc. 2,184,273 9.29
Federated Investors, Inc. 1,973,000 8.39
James R. Singer 1,800,000 7.66
Intrinsic Value Asset Management Inc. 1,263,253 5.37
Dimensional Fund Advisors Inc. 1,204,151 5.12
Directors and officers as a group (8 people) 1,052,481 4.37
Other Information
Headquarters: 10390 Pacific Center Court, San Diego, CA 92121; (858) 646-1100; fax (619) 453-5885.
Web site: www.vical.com.
Auditors: Deloitte & Touche LLP.
Employees: 169.
Industry: Biotechnology.
Information was compiled from the company’s annual and proxy reports.
